Measuring the Efficacy of Tafamidis as a Treatment for ATTR-CM
source: pixabay.com

Measuring the Efficacy of Tafamidis as a Treatment for ATTR-CM

When a disease is progressive, it can be difficult to discern if treatment is working. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an example, especially as its treatment, tafamidis, presents "relatively few…

Continue Reading Measuring the Efficacy of Tafamidis as a Treatment for ATTR-CM
Rare Classroom: Wilms’ Tumor
source: shutterstock

Rare Classroom: Wilms’ Tumor

Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…

Continue Reading Rare Classroom: Wilms’ Tumor
Compassion: The Staff at Cardinal Glennon’s Hospital Supported Joey and His Nephew’s Fight Against Acute Lymphoblastic Leukemia
source: pixabay.com

Compassion: The Staff at Cardinal Glennon’s Hospital Supported Joey and His Nephew’s Fight Against Acute Lymphoblastic Leukemia

Compassion [kuhm-pash-uhn] noun A feeling of deep sympathy and sorrow for another who is stricken by misfortune, accompanied by a strong desire to alleviate the suffering. Compassion Corner is a…

Continue Reading Compassion: The Staff at Cardinal Glennon’s Hospital Supported Joey and His Nephew’s Fight Against Acute Lymphoblastic Leukemia
Newly FDA Approved Ketamine Has the Potential to Slow ALS Progression
qimono / Pixabay

Newly FDA Approved Ketamine Has the Potential to Slow ALS Progression

An October 2021 report published in the Globe and Newswire carried an announcement by Fabio Chianelli, CEO of the biotech company PharmaTher Holdings. The FDA approved orphan drug status for…

Continue Reading Newly FDA Approved Ketamine Has the Potential to Slow ALS Progression
Nemvaleukin Alfa + Pembrolizumab Earn Fast Track Designation for Ovarian Cancer
source: pixabay.com

Nemvaleukin Alfa + Pembrolizumab Earn Fast Track Designation for Ovarian Cancer

Sometimes, treatments used in conjunction with each other can confer benefits for patients. According to the Cancer Network, for example, treating platinum-resistant ovarian cancer using nemvaleukin alfa and pembrolizumab (Keytruda)…

Continue Reading Nemvaleukin Alfa + Pembrolizumab Earn Fast Track Designation for Ovarian Cancer

A New Collaboration Could Bring A New CLN2 Batten Disease Treatment To Patients Faster

LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies have just announced their collaborative partnership. The aim is to develop and ultimately manufacture the AAV-mediated gene therapies developed by LEXEO. LEXEO LEXEO is…

Continue Reading A New Collaboration Could Bring A New CLN2 Batten Disease Treatment To Patients Faster